NFKB1 and colitis: The therapeutic effect of SSP on colitis with SKYD syndromes might be related to the inhibition of the TLR4/NF-κB signaling pathway, which corrects the immune interactions of GM or microflora metabolites with infDCs, and then maintains the symbiotic relationship between the microflora and the host (Figure 8).